Mazdutide Shows Significant Weight Loss in Phase 3 Trial
Key Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%
Read MoreKey Summary Mazdutide, a dual GLP-1 and glucagon receptor agonist, achieved 16.65% mean weight loss in adults with obesity. 84.3%
Read MoreKey Points at a Glance Large randomized clinical trials confirm that statins rarely cause reported side effects. Statins remain highly
Read More